Journal
ANTIVIRAL RESEARCH
Volume 97, Issue 1, Pages 36-40Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2012.10.011
Keywords
Hepatitis C; Direct-acting antivirals; Human immunodeficiency virus; Telaprevir; Boceprevir; Antiviral therapy
Categories
Funding
- Fundacion Investigacion y Educacion en SIDA (F-IES)
- Red de Investigacion en SIDA (RIS) [RD06/0006]
- European Network of AIDS Trials (NEAT) [LSHP-CT-2006-037570]
Ask authors/readers for more resources
The approval of the first protease inhibitors as treatment for hepatitis C virus (HCV) infection is rapidly transforming the way patients with chronic hepatitis C are managed. Treatment regimens are moving to combinations given for shortened periods, excluding poorly tolerated subcutaneous interferon, and providing rates of cure exceeding 75%. The recognition of HCV infection as a systemic disease, not limited to producing liver damage, in which extrahepatic complications play a major role as the cause of morbidity and mortality, is prompting the treatment of a growing number of HCV-infected individuals. However, new challenges are emerging, including the need to diagnose a substantial proportion of asymptomatic carriers, the risk of potentially harmful drug-drug interactions and the high cost of medications. The future will probably see a progressive marginalization of residual HCV populations, with increasing over-representation of illegal immigrants, alcohol abusers, intravenous drug users and the mentally disabled. (C) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available